Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study
Advances in Therapy · 2025
DOI: 10.1007/s12325-024-03100-8 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Advances in Therapy, 2025. Verfasst von Mark G Lebwohl und 19 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Psoriasis, Adalimumab, Biosimilar Pharmaceuticals, Drug Substitution. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Celltrion.
Abstract (Originalsprache)
INTRODUCTION: This study aimed to demonstrate the interchangeability of biosimilar CT-P17 and European Union reference adalimumab (EU-adalimumab) in a repeated-switch scenario. METHODS: In this ongoing, randomized, double-blind, active-controlled, phase 3 study, adults with moderate-to-severe plaque psoriasis received 80 mg EU-adalimumab on day 1, then 40 mg 1 week later and every other week until week 11. At week 13, patients were randomized (1:1, via an interactive web response system) to continue EU-adalimumab ("continuous" group) or undergo repeated switches between CT-P17 and EU-adalimumab ("switching" group). Dosing was via subcutaneous administration. The primary endpoints were area under the concentration-time curve and maximum serum concentration between weeks 25 and 27 (AUCtau,W25-27 and Cmax,W25-27, respectively). Secondary endpoints comprised additional pharmacokinetic (PK) parameters, efficacy, safety, and immunogenicity. Week 27 findings are presented. RESULTS: The first patient provided signed informed consent on November 7, 2022. Week 27 visits were completed by August 14, 2023. Of 367 patients enrolled, 346 were randomized (switching group, n = 172; continuous group, n = 174). The ratios of least squares means between groups and associated 90% confidence intervals (CIs) for AUCtau,W25-27 and Cmax,W25-27 were 99.45% (94.11-105.08%) and 100.45% (95.03-106.17%), respectively. For both endpoints, 90% CIs fell within the predefined equivalence margin of 80-125% and criteria were greater than calculated t values, satisfying bioequivalence. Additional PK endpoints and efficacy, safety, and immunogenicity findings were similar between groups. Safety profiles were in line with those previously reported. CONCLUSIONS: Week 27 primary PK results demonstrated bioequivalence, and the overall study results supported the interchangeability of CT-P17 and EU-adalimumab. TRIAL REGISTRATION: ClinicalTrials.gov, NCT05495568.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- UCSF Psoriasis and Skin Treatment Center, San Francisco, CA, USA.
- Centrum Medyczne Reuma Park, Warsaw, Poland.
- Reuma Centrum, Warsaw, Poland.
- ClinicMed Daniluk, Nowak Sp.K, Białystok, Poland.
- Centrum Medyczne AMED, Warsaw, Poland.
ORCID-Profile: Jakub Trefler, SungHyun Kim, YunJu Bae
Förderung
- Celltrion
Zitieren
APA
Lebwohl, M. G., Koo, J. Y., Jaworski, J., Trefler, J., Daniluk, S., Dudek, A., Baran, W., Owczarek, W., Kolinek, J., Brzewski, P., Sikora, M., Krogulec, M., Kim, S., Bae, Y., Jeon, D., Choi, E., Cha, J., Lee, H., Choi, S., & Pariser, D. M. (2025). Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study. Advances in Therapy. https://doi.org/10.1007/s12325-024-03100-8
Vancouver
Lebwohl MG, Koo JY, Jaworski J, Trefler J, Daniluk S, Dudek A, et al. Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study. Advances in Therapy. 2025. doi:10.1007/s12325-024-03100-8
BibTeX
@article{Lebwohl2025,
author = {Lebwohl, Mark G and Koo, John Y and Jaworski, Janusz and Trefler, Jakub and Daniluk, Stefan and Dudek, Anna and Baran, Wojciech and Owczarek, Witold and Kolinek, Joanna and Brzewski, Paweł and Sikora, Mariusz and Krogulec, Marek and Kim, SungHyun and Bae, YunJu and Jeon, DaBee and Choi, EunJin and Cha, JungBin and Lee, HyunJin and Choi, SuJin and Pariser, David M},
title = {Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study},
journal = {Advances in Therapy},
year = {2025},
doi = {10.1007/s12325-024-03100-8}
}
EUVIMED